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Background: RESCUE and REVERSE were 2 Phase 3 clinical
trials that assessed the efﬁcacy and safety of intravitreal
gene therapy with lenadogene nolparvovec (rAAV2/2-ND4)
for the treatment of Leber hereditary optic neuropathy
(LHON). RESTORE is the long-term follow-up study of subjects treated in the RESCUE and REVERSE trials.
Methods: In RESCUE and REVERSE, 76 subjects with LHON
because of the m.11778 G.A mutation in the mitochondrial gene ND4 received a single unilateral intravitreal injection of lenadogene nolparvovec. After 96 weeks, 61
subjects were enrolled in the long-term follow-up study
RESTORE. The best-corrected visual acuity (BCVA) was assessed over a period of up to 52 months after onset of
vision loss. A locally estimated scatterplot smoothing
regression model was used to analyze changes in BCVA
over time. Vision-related quality of life was reported using
the visual function questionnaire-25 (VFQ-25).
Results: The population of MT-ND4 subjects enrolled in
RESTORE was representative of the combined cohorts of
RESCUE and REVERSE for mean age (35.1 years) and gender distribution (79% males). There was a progressive and
sustained improvement of BCVA up to 52 months after the
onset of vision loss. The ﬁnal mean BCVA was 1.26 logarithm of the minimal angle of resolution 48 months after the
onset of vision loss. The mean VFQ-25 composite score
increased by 7 points compared with baseline.
Conclusion: The treatment effect of lenadogene nolparvovec on BCVA and vision-related quality of life observed 96
weeks (2 years) after treatment in RESCUE and REVERSE
was sustained at 3 years in RESTORE, with a maximum
follow-up of 52 months (4.3 years) after the onset of vision
loss.
Journal of Neuro-Ophthalmology 2021;41:309–315
doi: 10.1097/WNO.0000000000001367
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L

eber hereditary optic neuropathy (LHON) is a rare maternally inherited mitochondrial disease that primarily affects
retinal ganglion cells (RGCs) and leads to irreversible bilateral,
often sequential, severe vision loss (1). Three primary point
mutations affecting mitochondrial DNA (mtDNA) are
responsible for 90% of LHON cases (2): m.11778G.A in
the MT-ND4 gene, m.3460G.A in the MT-ND1 gene, and
m.14484T.C in the MT-ND6 gene. MT-ND genes encode
the mtDNA-related subunits of complex I, a key component
of the respiratory chain. The LHON mutations impair complex I activity, leading to decreased efﬁciency in adenosine
triphosphate (ATP) synthesis, accumulation of reactive oxygen species, eventually leading to RGCs degeneration and
apoptosis.
The m.11778G.A mutation is the most prevalent and is
associated with a poor visual prognosis (3). A recent metaanalysis reported that only 14.4% of patients with LHON of
all ages, and 11.3% of those aged 15 years or older, carrying the
m.11778G.A mutation (hereafter referred to as MT-ND4
patients), had visual recovery, although deﬁnitions of “recovery”
varied greatly among studies (3). LHON is an orphan disease,
with yet unmet therapeutic needs. Despite the European
approval under exceptional circumstances of the oral drug idebenone (a synthetic ubiquinone analog) for the treatment of
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LHON (2,4,5), there is still a pressing medical need for further
therapies with signiﬁcant beneﬁt in LHON.
In the last decade, gene therapies for LHON were
developed based on the allotopic nuclear expression of
therapeutic mitochondrial genes. Lenadogene nolparvovec
(rAAV2/2-ND4) is an adeno-associated viral vector containing the modiﬁed cDNA encoding the human wild-type
mitochondrial ND4 protein, ﬂanked by 2 mitochondrial
targeting sequences. This expresses the therapeutic mRNA
from the intranuclear episomes, which in turn is translated
by ribosomes at the surface of mitochondria, and, ultimately, the resulting therapeutic ND4 protein is translocated into the mitochondrial matrix. The therapeutic
ND4 protein can then integrate into complex I to restore
the electron ﬂow and respiration. In vitro, lenadogene nolparvovec was able to improve ATP synthesis in ﬁbroblasts of
MT-ND4 patients (6,7). In rodent models of LHON with

ND4-induced complex I deﬁciency, lenadogene nolparvovec prevented optic atrophy and vision loss (8). Administered as a unilateral intravitreal injection to MT-ND4
patients, lenadogene nolparvovec showed a good safety proﬁle in a phase 1/2 clinical trial including 5 years of followup after treatment administration (9). Two phase 3 clinical
trials—RESCUE and REVERSE—assessed the efﬁcacy and
safety of a unilateral intravitreal injection of lenadogene
nolparvovec within 1 year of visual loss in MT-ND4
patients (10,11). Unexpectedly, in the group of fellow eyes
that received a sham injection, the best-corrected visual
acuity (BCVA) improved similarly to the group of eyes
injected with lenadogene nolparvovec. Two years after treatment administration, a clinically signiﬁcant bilateral
improvement of BCVA from nadir (i.e., the lowest individual BCVA recorded during the trials) was reported in both
studies, with a mean gain between 20.46 and 20.57
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logarithm of the minimal angle of resolution (logMAR)
(+23 to +29 Early-Treatment Diabetic Retinopathy Study
[ETDRS] letters equivalent) (10,11).
This report presents interim results of RESTORE, the
long-term follow-up study of RESCUE and REVERSE, 3
years after treatment administration.

Institute (NEI) Visual Function Questionnaire (VFQ)-25, the
25-item version of the 51-item NEI Visual Function Questionnaire. The VFQ-25 consists of 25 vision-targeted questions
representing 11 vision-related constructs, plus an additional
single-item general health rating question. The overall composite
score for the VFQ-25 is the average of the vision-targeted
subscales scores, excluding the general health rating question (12).

METHODS

Data Analyses

Design of the RESCUE and REVERSE Trials and
Their Long-Term Follow-Up Study RESTORE
RESCUE (NCT02652767) and REVERSE (NCT02652780)
were 2 randomized, double-masked, sham-controlled, Phase 3
clinical trials assessing the efﬁcacy of lenadogene nolparvovec
gene therapy for the treatment of LHON in MT-ND4 subjects who had vision loss due to LHON in at least one eye and
were at least 15 years old at screening. Each patient’s right eye
was randomized to receive either a single intravitreal injection
of lenadogene nolparvovec (9E10 viral genomes in 90 mL) or a
sham intravitreal injection (the blunt edge of a needleless
syringe was applied at the regular site of injection). The contralateral left eye received the treatment not allocated to the
right eye. The objective was to evaluate the efﬁcacy of lenadogene nolparvovec compared with a sham injection at weeks
48 (primary endpoint) and 96, using the difference in change
in BCVA from baseline. The only difference between the 2
clinical trials was the duration of vision loss at screening, with
RESCUE enrolling subjects with vision loss in at least one eye
for less than 6 months and REVERSE enrolling subjects with
vision loss for 6–12 months in both eyes.
Ninety-six weeks after treatment administration in
RESCUE and REVERSE, subjects were offered to participate in RESTORE—the long-term follow-up study of
RESCUE and REVERSE—for another 3 years, corresponding to 5 years post-treatment administration (Fig. 1).

Outcome Measures
In this publication, we report the outcome measures of BCVA
and vision-related quality of life. BCVA was assessed using the
Early-Treatment Diabetic Retinopathy Study letter chart at 1 or
4 m. Quality of life was monitored using the National Eye

The RESTORE long-term follow-up study is still ongoing.
A database freeze was performed on May 29, 2020, when all
the active participants had completed their year 3 visit. One
RESCUE subject who had received a partial dose of
lenadogene nolparvovec was included in the analysis as a
conservative approach.

Handling of Best-Corrected Visual Acuity Data
All BCVA measures were converted into logMAR. On-chart
BCVA was converted into logMAR using the standard
formula (13). Off-chart BCVA of counting ﬁngers and
hand motion were assigned a value of 2.0 and 2.3 logMAR,
respectively, as described by Lange et al (14). Eyes with light
perception and no light perception vision were assigned an
arbitrary value of 4.0 and 4.5 logMAR, respectively.

Visual Function Questionnaire-25
Because all subjects received the active product, the
treatment effect of lenadogene nolparvovec on the patients’
quality of life was assessed in all subjects. The change from
baseline of the VFQ-25 composite score and subscale scores
was measured in each patient. A 4-point to 6-point change
in NEI VFQ-25 scores represents a clinically meaningful
change for each score (15).

Statistical Analysis
We explored graphically the evolution of BCVA starting at 12
months after vision loss, at which time all REVERSE and
RESCUE patients would have been treated with lenadogene
nolparvovec, using a locally estimated scatterplot smoothing
(LOESS) nonparametric local regression model in which each
patient’s eyes were considered independently. Owing to the
contralateral effect of lenadogene nolparvovec previously

FIG. 1. Study design of RESCUE and REVERSE and their long-term follow-up study RESTORE. RESCUE and REVERSE subjects
were followed for 2 years (96 weeks) after which they were offered to participate in the long-term follow-up study RESTORE.
The average time between the onset of vision loss and treatment administration was 3.9 months in RESCUE subjects and
9.8 months in REVERSE subjects. n: number of study participants at key time points.
Biousse et al: J Neuro-Ophthalmol 2021; 41: 309-315
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demonstrated in RESCUE and REVERSE (10,11), all eyes
were included in this analysis regardless of whether they had
received an injection of lenadogene nolparvovec or a sham
injection. The smoothing parameter of the LOESS model
was based on the corrected Akaike Information Criterion
(AICc) (SAS default method with values from 0.3 to 0.6).
The LOESS curve was presented with a 95% conﬁdence interval (CI).

RESULTS
Characteristics of the Analyzed Population and
Follow-Up Time
A total of 76 patients (152 eyes) were treated in the RESCUE
and REVERSE trials. The RESCUE trial included 39 subjects
and was completed in September 2019. The REVERSE trial
included 37 subjects and was completed in April 2019.
Subjects were mostly male (80.3%) with a mean (SD) age of
35.0 (15.3) years (Table 1). Nine (11.8%) subjects were below
the age of 18 (Table 1).
Of the 76 subjects, 72 completed the 2-year study
follow-up and 62 (86.1%) agreed to participate in the longterm follow-up study RESTORE. One patient discontinued
the RESTORE study before attending the ﬁrst visit,
scheduled 2.5 years after treatment administration, and
was therefore excluded from the demographics analysis of
RESTORE (n = 61) (Fig. 1).
Subjects enrolled in RESTORE were mostly male (78.7%)
and had a mean (SD) age of 35.1 (15.4) years, including 7
(11.4%) subjects below the age of 18 years when initially
enrolled in REVERSE and RESCUE (Table 1).
The mean number of visual acuity assessments per
patient was 26.8. Patients had a median follow-up duration
after vision loss of 39.8 months, with a quarter of patients
followed for more than 44.1 months and a maximal followup of 51.5 months.

Visual Outcomes
Patients received treatment between 2.3 and 12.8 months
after onset of vision loss (median 6.5 months; mean 7.4
months). Half of the eyes (53.8%) had received treatment
at Month 6 ([3–9] months) after vision loss, nearly all eyes
(92.7%) were treated at Month 12 ([9–15] months), and all
patients (100%) at Month 18 ([15–21] months). We
started BCVA analyses at Month 12, when 92.7% of eyes
(139/150) had received treatment (Table 2). The LOESS
analysis was run using all the BCVA data collected in the
152 eyes of subjects treated in RESCUE and REVERSE,
from Month 12 to the last available measure, corresponding
to 51.5 months after the onset of vision loss for the last
available data point in the RESTORE study.
The LOESS regression model based on a scatterplot of
individual BCVA data showed a progressive and sustained
BCVA improvement from 12 to 51.5 months after onset
(Fig. 2). The mean (SD) BCVA steadily improved from
1.57 (0.55) logMAR at 12 months after the onset of vision
loss to 1.26 (0.45) logMAR at 48 months after onset (Table
2). The mean BCVA of MT-ND4 subjects remained onchart, that is, better than 1.6 logMAR, throughout the
follow-up period. The absolute difference in change from
baseline between drug-treated and sham-treated eyes was
0.006 logMAR 2 years after treatment administration and
0.018 logMAR 3 years after treatment administration.

Quality of Life
Most of the VFQ-25 metrics showed a clinically meaningful
improvement from baseline to week 96: mental health (+16
points), dependency (+13 points), role difﬁculties (+12
points), near activities (+5 points), and general vision (+5
points). Overall, the composite score showed a clinically
meaningful improvement of +4 points. At 3 years after
treatment, a clinically meaningful overall improvement of
quality of life was reported, with a mean gain of 7 points
from baseline for the composite score (Table 3). Similarly,
many subscales showed a clinically meaningful improvement from baseline: mental health (+21 points), role

TABLE 1. Characteristics of the analyzed population
Demographics*
Sex, n (%)
Male
Female
Age at onset, yrs
Mean (SD)
Min, max
Subjects ,18 yrs old at onset, n (%)*
Yes
No

Subjects in RESCUE and REVERSE
n = 76

Subjects in RESTORE
n = 61

61 (80.3%)
15 (19.7%)

48 (78.7%)
13 (21.3%)

35.0 (15.3)
15–69

35.1 (15.4)
15–69

9 (11.8%)
67 (88.2%)

7 (11.5%)
54 (88.5%)

*Subjects had to be at least 15 years old to be enrolled in RESCUE and REVERSE.
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TABLE 2. Evolution of the best-corrected visual acuity
(BCVA) in MT-ND4 patients treated with lenadogene
nolparvovec

difﬁculties (+17 points), dependency (+15 points), general
vision (+9 points), near activities (+6 points), and distance
activities (+5 points) (Table 3).

BCVA—LogMAR

DISCUSSION

12 (9–15) months after the
onset of vision loss
n (eyes)
Mean BCVA (SD)
95% CI
18 (15–21) months after the
onset of vision loss
n (eyes)
Mean BCVA (SD)
95% CI
24 (21–30) months after the
onset of vision loss
n (eyes)
Mean BCVA (SD)
95% CI
36 (30–42) months after the
onset of vision loss
n (eyes)
Mean BCVA (SD)
95% CI
48 (42–54) months after the
onset of vision loss
n (eyes)
Mean BCVA (SD)
95% CI

150
1.57 (0.55)
1.48; 1.66

149
1.46 (0.51)
1.38; 1.54

146
1.40 (0.59)
1.30; 1.50

128
1.33 (0.59)
1.23; 1.44

62
1.26 (0.45)
1.14; 1.37

At each time point, the mean and 95% CIs were calculated on the
individual BCVA data collected in the period indicated between
brackets. For example, the 12-month mean BCVA is the average of
150 individual BCVA data points collected between 9 and 15
months after the onset of vision loss.
CI, conﬁdence interval; logMAR, logarithm of the minimal angle
resolution.

Long-term follow-up of MT-ND4 subjects included in the
RESCUE and REVERSE studies who were treated with a
single unilateral intravitreal injection of lenadogene nolparvovec demonstrated a progressive and sustained improvement of BCVA in both eyes and improvement of quality
of life up to 52 months after the onset of vision loss.
Sixty-two of 72 subjects who completed RESCUE or
REVERSE agreed to participate in RESTORE. This substantial
retention rate of 86% indicates that the RESTORE cohort is a
representative of the entire study population. Indeed, the
demographics of the RESTORE cohort of MT-ND4 subjects
were very similar to the population originally treated. The mean
age at onset and gender distribution in RESCUE, REVERSE,
and RESTORE also corresponded to the typical LHON demographics reported in the literature (1,2).
The evolution of BCVA after treatment with lenadogene
nolparvovec showed a progressive and sustained improvement
up to 51.5 months (4.3 years) after the onset of vision loss.
The mean BCVA of treated subjects remained clearly on-chart,
contrary to the natural history of the disease reported in MTND4 patients aged 15 and over at onset (3). Importantly, the
continuous improvement of BCVA was reported in both eyes
of unilaterally treated subjects, conﬁrming the contralateral
treatment effect of lenadogene nolparvovec reported at earlier
time points in the RESCUE and REVERSE trials (10,11).
Indeed, the absolute difference in change from baseline

TABLE 3. Change in the visual function questionnaire-25 items (VFQ-25) subscale score at year 3 posttreatment administration
VFQ-25 Subscales*
Composite score
Mental health
Role difﬁculties
Dependency
General vision
Near activities
Distance activities
Social functioning
Color vision
Peripheral vision
Ocular pain

Baseline Score†
Mean (SD)
46.2
30.0
31.4
32.5
34.3
27.3
38.4
46.9
72.5
61.9
87.9

(16.3)
(21.5)
(26.3)
(25.8)
(16.5)
(20.4)
(20.4)
(25.5)
(28.8)
(26.9)
(18.0)

Change From Baseline at 3 Years After Treatment Administration
Mean (SD)†
+6.9
+21.2
+16.8
+15.0
+9.0
+5.9
+5.5
+3.5
20.8
21.2
27.8

(20.1)‡
(25.7)‡
(31.9)‡
(33.6)‡
(22.2)‡
(25.8)‡
(26.5)‡
(30.4)
(34.2)
(34.3)
(21.9)

*Subscales not reported in this table: general health (missing values) and driving (not applicable to LHON).
†
Mean scores calculated in the 61 subjects who completed the year 3 visit.
‡
Scores and subscores with a clinically meaningful improvement (15).
Biousse et al: J Neuro-Ophthalmol 2021; 41: 309-315
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FIG. 2. Evolution of the best-corrected visual acuity (BCVA) in MT-ND4-LHON subjects treated in RESCUE and REVERSE. The
LOESS curve of the evolution of BCVA in all eyes is presented over time from 12 months to 51.5 months (last available data
point) after the onset of vision loss.

between drug-treated and sham-treated eyes was similar 2 and
3 years after treatment administration.
Because all MT-ND4 subjects were treated with lenadogene nolparvovec, an intrapatient comparison before and
after treatment was used to assess the impact of treatment
on quality of life, highlighting daily beneﬁts experienced by
each treated patient. In the overall REVERSE and RESCUE
population, most of the quality-of-life metrics showed a clinically meaningful improvement from baseline to week 96,
consistent with reported improvement of the visual acuity
(10,11). Similarly at 3 years after treatment, this clinically
meaningful improvement of most metrics was maintained,
consistent with the persistence of the treatment effect of
lenadogene nolparvovec on BCVA. The worsening of the
ocular pain score (Table 3) may be related to the occurrence
of intraocular inﬂammation experienced by some patients
during the REVERSE and RESCUE studies (10,11).
By design, gene therapy is assumed to be a treatment
with a one-time administration. As such, the long-term
beneﬁts of a single dose of gene therapy need to be
persistent over time. Here, we report that the efﬁcacy of a
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single unilateral intravitreal injection of lenadogene nolparvovec on visual acuity and vision-related quality of life was
clinically meaningful and sustained up to 4.3 years after the
onset of vision loss. This report sheds promising light on the
use of gene therapy in LHON, a disease with a pressing
medical need for therapies with signiﬁcant beneﬁt.
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